A cost-effectiveness analysis of palbociclib plus letrozole as first-line treatment for estrogen receptor-positive, HER2-negative, metastatic breast cancer.

被引：2
|
作者：
Matter-Walstra, Klazien
Schwenkglenks, Matthias
Brauchli, Peter
Klingbiel, Dirk
Dedes, Konstantin J.
机构：
[1] Univ Basel, Inst Pharmaceut Med, ECPM, Basel, Switzerland
[2] Swiss Grp Clin Canc Res SAKK, Bern, Switzerland
[3] SAKK Swiss Grp Clin Canc Res, Coordinating Ctr, Bern, Switzerland
[4] Univ Zurich Hosp, Zurich, Switzerland
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.567
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
567
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Palbociclib for the Treatment of Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Morikawa, Aki
    Henry, N. Lynn
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (16) : 3591 - 3596
  • [2] Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
    K. Matter-Walstra
    M. Schwenkglenks
    K. J. Dedes
    [J]. Breast Cancer Research and Treatment, 2017, 163 : 635 - 635
  • [3] Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting
    Matter-Walstra, K.
    Schwenkglenks, M.
    Dedes, K. J.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2017, 163 (03) : 635 - 635
  • [4] Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer
    Kahraman, Seda
    Erul, Enes
    Seyyar, Mustafa
    Gumusay, Ozge
    Bayram, Ertugrul
    Demirel, Burcin Cakan
    Acar, Omer
    Aksoy, Sercan
    Baytemur, Naziyet Kose
    Sahin, Elif
    Cabuk, Devrim
    Basaran, Gul
    Paydas, Semra
    Yaren, Arzu
    Guven, Deniz Can
    Erdogan, Atike Pinar
    Demirci, Umut
    Yasar, Alper
    Bayoglu, Ibrahim Vedat
    Hizal, Mutlu
    Gulbagci, Burcu
    Paksoy, Nail
    Davarci, Sena Ece
    Yilmaz, Funda
    Dogan, Ozlem
    Orhan, Sibel Oyucu
    Kayikcioglu, Erkan
    Aytac, Ali
    Keskinkilic, Merve
    Mocan, Eda Eylemer
    Unal, Olcun Umit
    Aydin, Esra
    Yucel, Hakan
    Isik, Deniz
    Eren, Onder
    Uluc, Basak Oyan
    Ozcelik, Melike
    Hacibekiroglu, Ilhan
    Aydiner, Adnan
    Demir, Hacer
    Oksuzoglu, Berna
    Cilbir, Ebru
    Cubukcu, Erdem
    Cetin, Bulent
    Oktay, Esin
    Erol, Cihan
    Okutur, Sadi Kerem
    Yildirim, Nilgun
    Alkan, Ali
    Selcukbiricik, Fatih
    [J]. FUTURE ONCOLOGY, 2023, : 727 - 736
  • [5] COST-EFFECTIVENESS ANALYSIS OF PALBOCICLIB PLUS FULVESTRANT VERSUS EVEROLIMUS PLUS EXEMESTAN IN THE TREATMENT OF ESTROGEN RECEPTOR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER IN IRAN
    Taheri, S.
    Majd, Karimi Z.
    Rezaei, S.
    Yousefi, N.
    Peiravian, F.
    [J]. VALUE IN HEALTH, 2019, 22 : S472 - S472
  • [6] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Zhang, Bingnan
    Long, Elisa F.
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2019, 175 (03) : 775 - 779
  • [7] Cost-effectiveness analysis of palbociclib or ribociclib in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer
    Bingnan Zhang
    Elisa F. Long
    [J]. Breast Cancer Research and Treatment, 2019, 175 : 775 - 779
  • [8] FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
    Beaver, Julia A.
    Amiri-Kordestani, Laleh
    Charlab, Rosane
    Chen, Wei
    Palmby, Todd
    Tilley, Amy
    Zirkelbach, Jeanne Fourie
    Yu, Jingyu
    Liu, Qi
    Zhao, Liang
    Crich, Joyce
    Chen, Xiao Hong
    Hughes, Minerva
    Bloomquist, Erik
    Tang, Shenghui
    Sridhara, Rajeshwari
    Kluetz, Paul G.
    Kim, Geoffrey
    Ibrahim, Amna
    Pazdur, Richard
    Cortazar, Patricia
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (21) : 4760 - 4766
  • [9] Cost-effectiveness of lapatinib plus letrozole in HER2-positive, hormone receptor-positive metastatic breast cancer in Canada
    Delea, T. E.
    Amdahl, J.
    Chit, A.
    Amonkar, M. M.
    [J]. CURRENT ONCOLOGY, 2013, 20 (05) : E371 - E387
  • [10] Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer?
    Kim, Ji-Yeon
    Oh, Jung Min
    Park, Yeon Hee
    Ahn, Jin Seok
    Im, Young-Hyuck
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
12345